Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: A phase II/III study

被引：1
|
作者：
Parsons, S.
Murawa, P. X.
Koralewski, P.
Kutarska, E.
Kolesnik, O. O.
Stroehlein, M. A.
Lahr, A.
Jaeger, M.
Heiss, M. M.
机构：
[1] City Hosp Nottingham, Nottingham, England
[2] Oddzial Chirurg Onkol, Poznan, Poland
[3] Oddzial Chemioterapii Wojewodzki, Krakow, Poland
[4] Oddzial III Onkol Ginekol, Lublin, Poland
[5] Inst Oncol Acad Med Sci, Kiev, Ukraine
[6] Klinikum Koeln Merheim, Cologne, Germany
[7] Fresenius Biotech GmbH, Munich, Germany
[8] TRION Res GmbH, Martinsried, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3000
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Intraperitoneal administration of the trifunctional antibody catumaxomab for treatment of malignant ascites due to ovarian carcinoma: Results of a phase II/III study
    Parsons, S.
    Kutarska, E.
    Koralewski, P.
    Gore, M.
    Wimberger, R.
    Burges, A.
    Sroehlein, M. A.
    Friccius-Quecke, H.
    Jaeger, M.
    Heiss, M. M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 311 - 311
  • [2] The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial
    Heiss, Markus M.
    Murawa, Pawel
    Koralewski, Piotr
    Kutarska, Elzbieta
    Kolesnik, Olena O.
    Ivanchenko, Vladimir V.
    Dudnichenko, Alexander S.
    Aleknaviciene, Birute
    Razbadauskas, Arturas
    Gore, Martin
    Ganea-Motan, Elena
    Ciuleanu, Tudor
    Wimberger, Pauline
    Schmittel, Alexander
    Schmalfeldt, Barbara
    Burges, Alexander
    Bokemeyer, Carsten
    Lindhofer, Horst
    Lahr, Angelika
    Parsons, Simon L.
    INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (09) : 2209 - 2221
  • [3] Results of a phase II clinical trial to evaluate a re-challenge of intraperitoneal catumaxomab for treatment of malignant ascites (MA) due to epithelial cancer (SECIMAS).
    Pietzner, Klaus
    Vergote, Ignace
    Santoro, Armando
    Marme, Frederik
    Rosenberg, Per
    Friccius-Quecke, Hilke
    Sehouli, Jalid
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Phase II clinical trial to evaluate the safety of repeated cycles of intraperitoneal catumaxomab for the treatment of malignant ascites (SECIMAS)
    Pietzner, K.
    Linke, R. G.
    Jaeger, M.
    Lindhofer, H.
    Friccius-Quecke, H.
    Chen, F.
    Braicu, E. I.
    Oskay-Oezcelik, G.
    Sehouli, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer
    Fausto Petrelli
    Karen Borgonovo
    Veronica Lonati
    Stefano Elia
    Sandro Barni
    Targeted Oncology, 2013, 8 : 291 - 294
  • [6] Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer
    Petrelli, Fausto
    Borgonovo, Karen
    Lonati, Veronica
    Elia, Stefano
    Barni, Sandro
    TARGETED ONCOLOGY, 2013, 8 (04) : 291 - 294
  • [7] Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: Results of a phase II/III study
    Parsons, S. L.
    Kutarska, E.
    Koralewski, P.
    Gore, M.
    Wimberger, P.
    Burges, A.
    Stroehlein, M. A.
    Lahr, A.
    Jaeger, M.
    Heiss, M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study
    Sehouli, Jalid
    Pietzner, Klaus
    Wimberger, Pauline
    Vergote, Ignace
    Rosenberg, Per
    Schneeweiss, Andreas
    Bokemeyer, Carsten
    Salat, Christoph
    Scambia, Giovanni
    Berton-Rigaud, Dominique
    Santoro, Armando
    Cervantes, Andres
    Tredan, Olivier
    Tournigand, Christophe
    Colombo, Nicoletta
    Dudnichenko, Alexander S.
    Westermann, Anneke
    Friccius-Quecke, Hilke
    Lordick, Florian
    MEDICAL ONCOLOGY, 2014, 31 (08)
  • [9] Decrease of VEGF within malignant ascites during catumaxomab treatment: Results from a pivotal phase II/III study
    Jaeger, M.
    Schoberth, A.
    Theissen, B.
    Hess, J.
    Friccius-Quecke, H.
    Lindhofer, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] The trifunctional antibody catumaxomab: Clinical experience in the treatment of malignant ascites due to gynecological tumors
    Marmé F.
    Der Gynäkologe, 2011, 44 (11): : 917 - 923
12345